Trevi Therapeutics, Inc.
Get verified emails for Trevi Therapeutics, Inc. employees
About Trevi Therapeutics, Inc.
|
|
|
11-50 employees
View all Trevi Therapeutics, Inc. employees
|
|
Biotechnology
|
|
195 Church Street, 14th Floor, New Haven, CT 06510, US
|
|
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough.
Trevi is headquartered in New Haven, CT.
|
Trevi Therapeutics, Inc. Alternatives
Frequently Asked Questions about Trevi Therapeutics, Inc.
Who are the decision makers in Trevi Therapeutics, Inc.?
The decision makers in Trevi Therapeutics, Inc. are Angela Hudson Davis, Catherine Weenink, Danine Summers, etc. Click to Find Trevi Therapeutics, Inc. decision makers emails.
Trevi Therapeutics, Inc. Staff Directory
Search Trevi Therapeutics, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Search Portal
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
